BindingDB logo
myBDB logout

19 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
24513044 19 Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agent.EBI Bristol-Myers Squibb
24411477 84 Carbamazepine derivatives with P2X4 receptor-blocking activity.EBI University of Bonn
24164581 82 Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist.EBI Bristol-Myers Squibb Company
24246730 34 Design and synthesis of potent and selective P2X3 receptor antagonists derived from PPADS as potential pain modulators.EBI Gwangju Institute of Science and Technology (GIST)
23510563 9 Synthesis and structure-activity relationships of carboxylic acid derivatives of pyridoxal as P2X receptor antagonists.EBI Gwangju Institute of Science and Technology
16250663 8 Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.EBI University of Bonn
20045645 66 Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.EBI Roche Palo Alto
23075067 98 N-substituted phenoxazine and acridone derivatives: structure-activity relationships of potent P2X4 receptor antagonists.EBI University of Bonn
21207957 163 Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor.EBI University of Bonn
11831909 4 Novel antagonists acting at the P2Y(1) purinergic receptor: synthesis and conformational analysis using potentiometric and nuclear magnetic resonance titration techniques.EBI Universit£ Louis Pasteur
12213051 207 Purine and pyrimidine (P2) receptors as drug targets.EBI National Institute of Diabetes
19231180 81 Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.EBI Roche Palo Alto LLC
19231178 61 Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.EBI Roche Palo Alto LLC
15927468 3 Discovery and synthesis of a novel and selective drug-like P2X(1) antagonist.EBI Roche Palo Alto
11462975 50 Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.EBI National Institute of Diabetes and Digestive and Kidney Diseases
9632352 7 A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors.EBI National Institute of Diabetes and Digestive and Kidney Diseases
15131245 86 SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.BDB Sanofi-Synthelabo Recherche
11111828 16 Agonists and antagonists acting at P2X receptors: selectivity profiles and functional implications.BDB Biocentre Niederursel
9454810 72 SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.BDB Sanofi Recherche